目的：探讨玻璃体腔注射康柏西普联合Ahmed青光眼阀植入及全视网膜光凝治疗有视功能的新生血管性青光眼的疗效和安全性。

方法：回顾分析我院2015-01/12有视功能的新生血管性青光眼患者12例12眼，行玻璃体腔注射康柏西普0.5mg，待虹膜新生血管消退后，行Ahmed青光眼阀植入术，2wk后行全视网膜光凝，术后随访3mo，观察视力、眼压和手术并发症等情况。

结果：随访3mo后，患者视力提高10眼，无变化1眼，视力下降1眼。平均眼压由术前41.22±8.29mmHg降至术后3mo的16.08±4.92mmHg，差异有统计学意义(P<0.05)。青光眼阀植入术后1眼患者发生了浅前房，1wk后完全恢复。1眼患者术后出现了少量前房积血，3d后完全吸收。1眼激光光凝术后1mo发生了玻璃体积血，行玻璃体切割后视力部分恢复，眼压控制良好。

结论：玻璃体腔注射康柏西普后植入Ahmed青光眼阀和进行全视网膜光凝是治疗有视功能的新生血管性青光眼的一种安全有效的方法。

AIM: To investigate the curative effect and safety of glass body cavity injection of Conbercept glass valve body cavity injection combined with Ahmed valve implantation and whole retinal photocoagulation in treatment of neovascular glaucoma with visual function.

METHODS: Retrospective analysis of our hospital from 2015 Jan. to 2015 Dec., 12 cases of neovascular glaucoma patients with visual function were treated with glass body cavity injection of Conbercept 0.5mg, after waiting for iris neovascular fade, glaucoma valve implantation and retinal photocoagulation. All the cases were follow-up for 3mo. Visual acuity, intraocular pressure, complications and so on were observed and recorded.

RESULTS: After 3mo follow-up, vision improvement 10 eyes, constant vision 1 eye and decreased vision 1 eyes average intraocular pressure decreased significantly(41.22±8.29 mmHg vs 16.08±4.92 mmHg, P<0.05). No serious complications were observed, only one eye was found shallow of anterior chamber, and recovered in 1wk. A small amount of blood in the anterior chamber was observed in 1 eye, and absorbed 3d later. Vitreous body hematocele was diagnosed in 1 eye treated with whole retinal photocoagulation after 1mo later. After vitreous body cutting applied, vision was partly recovered and intraocular pressure was stable.

CONCLUSION: Conbercept glass valve body cavity injection combined with Ahmed valve implantation and whole retinal photocoagulation treatment is a safe and effective method for neovascular glaucoma with visual function.